Lastly, our proof-of-principle findings in vivo indicated that RAC1-amplified and RAC1-A159V-mutated HNSCC could be potentially druggable with EHop-016, a preclinical Rac inhibitor. The gene discussed is RAC1; the disease is head and neck squamous cell carcinoma.